A plethora of gene therapies for hemoglobinopathies
- 1 February 2021
- journal article
- editorial
- Published by Springer Nature in Nature Medicine
- Vol. 27 (2), 202-204
- https://doi.org/10.1038/s41591-021-01235-7
Abstract
No abstract availableFunding Information
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NA see below)
- Funding from the intramural research program of the National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
This publication has 13 references indexed in Scilit:
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaNew England Journal of Medicine, 2021
- Gene therapy for severe combined immunodeficiencies and beyondThe Journal of Experimental Medicine, 2019
- Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemiaNature Medicine, 2019
- Gene Therapy in Patients with Transfusion-Dependent β-ThalassemiaNew England Journal of Medicine, 2018
- Gene therapy comes of ageScience, 2018
- At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCTBlood, 2017
- Gene Therapy in a Patient with Sickle Cell DiseaseNew England Journal of Medicine, 2017
- Lentiviral vectors, two decades laterScience, 2016
- Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobinCurrent Opinion in Genetics & Development, 2015
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010